Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159752 | 0.84 | TDP1 (0.64) | TDP1MAOBMAOAALDH1A1MAPK1 | |
| SCHEMBL56986 | 0.84 | TDP1 (0.59) | TDP1ALDH1A1MAPK1L3MBTL1APP | |
| SCHEMBL5441092 | 0.84 | ALDH1A1 (0.69) | TDP1MAOBMAOAALDH1A1MAPK1 | |
| SCHEMBL24405140 | 0.84 | TDP1 (0.54) | TDP1ALDH1A1MAPK1L3MBTL1APP | |
| SCHEMBL304176 | 0.84 | TDP1 (0.78) | TDP1ALDH1A1MAPK1L3MBTL1APP | |
| SCHEMBL1068218 | 0.83 | CYP4F2 (0.55) | TDP1MAOBMAOAALDH1A1THRA | |
| Ammonia Solution, Strong SCHEMBL28588274 | 0.82 | TDP1 (0.75) | TDP1ALDH1A1MAPK1L3MBTL1APP | |
| Bicarbonate SCHEMBL7699565 | 0.82 | TDP1 (0.75) | TDP1ALDH1A1MAPK1L3MBTL1APP | |
| SCHEMBL28207503 | 0.82 | TDP1 (0.75) | TDP1ALDH1A1MAPK1L3MBTL1APP | |
| SCHEMBL22276673 | 0.82 | TDP1 (0.56) | TDP1ALDH1A1MAPK1L3MBTL1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213040-A1 | CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| WO-2020234277-A1 | CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON S DISEASE | H. LUNDBECK A/S (DK) | 2020-11-26 | — | — | WO | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2004098609-A1 | BENZOTRIAZEPINE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213040-A1 | CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | COMT, CHAT, SLC6A2 | TDP1 307/4885MAOB 7/4885MAOA 14/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | TDP1 2782/4885MAOB 660/4885MAOA 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.